Cargando…

Subcutaneous in situ gel delivered leuprolide acetate's consistent and prolonged drug delivery maintains effective testosterone suppression independent of age and weight in men with prostate cancer

OBJECTIVES: To assess the impact of patient age and weight on the pharmacokinetics (PK), testosterone (T) suppression and safety from four fixed dosing regimens (7.5, 22.5, 30, or 45 mg for 1‐, 3‐, 4‐, or 6‐months, respectively) of subcutaneous in situ gel delivered leuprolide acetate (Gel‐LA) injec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Renzulli, Joseph F., Tagawa, Scott T., Atkinson, Stuart N., Boldt‐Houle, Deborah M., Moul, Judd W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988824/ https://www.ncbi.nlm.nih.gov/pubmed/35474709 http://dx.doi.org/10.1002/bco2.13

Ejemplares similares

THU195 6-Month Subcutaneous Leuprolide Acetate Achieved And Maintained Hormonal And Clinical Suppression In All Weight Groups Of Children With Central Precocious Puberty
por: Miller, Bradley S, et al.
Publicado: (2023)

6-Month Subcutaneous Leuprolide Acetate Effectively Suppresses Clinical Signs of Puberty in Children With Central Precocious Puberty
por: Eugster, Erica A, et al.
Publicado: (2021)

ODP397 Small-volume, Subcutaneous, 6-month Leuprolide Acetate Effectively Reduces Growth Velocity to Prepubertal Levels in Children with Central Precocious Puberty
por: Klein, Karen O, et al.
Publicado: (2022)

Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer
por: Spitz, A, et al.
Publicado: (2012)

Evaluation of Hypersensitivity Reactions with Leuprolide Acetate and Triptorelin Acetate in Children
por: Metbulut, Azize Pınar, et al.
Publicado: (2021)

Testosterone-Mediated Aggression in Angelman Syndrome Treated With Leuprolide and Orchiectomy
por: Anderson, Danyon J, et al.
Publicado: (2022)

Therapeutic Effects of Leuprorelin (Leuprolide Acetate) in Sexual Offenders with Paraphilia
por: Choi, Jong Hyuk, et al.
Publicado: (2018)

Pseudotumor cerebri in patient on leuprolide acetate for central precocious puberty
por: Omar, Anjumanara Anver, et al.
Publicado: (2020)

Clinical development of the GnRH agonist leuprolide acetate depot
por: Chwalisz, Kristof
Publicado: (2022)

Phase 3 Trial of a Small-volume Subcutaneous 6-Month Duration Leuprolide Acetate Treatment for Central Precocious Puberty
por: Klein, Karen O, et al.
Publicado: (2020)

Pharmacokinetic–Pharmacodynamic Model for the Testosterone-Suppressive Effect of Leuprolide in Normal and Prostate Cancer Rats
por: Lee, Dong-Seok, et al.
Publicado: (2018)

Leuprolide acetate induces structural and functional recovery of injured spinal cord in rats
por: Díaz Galindo, Carmen, et al.
Publicado: (2015)

Leuprolide Acetate 1-Month Depot for Central Precocious Puberty: Hormonal Suppression and Recovery
por: Neely, E. Kirk, et al.
Publicado: (2010)

In-vitro/In-vivo comparison of leuprolide acetate release from an in-situ forming plga system
por: Mashayekhi, Roya, et al.
Publicado: (2013)

Intramuscular depot formulations of leuprolide acetate suppress testosterone levels below a 20 ng/dL threshold: a retrospective analysis of two Phase III studies
por: Spitz, Aaron, et al.
Publicado: (2016)

Analysis of Adherence, Persistence, and Surgery Among Endometriosis Patients Treated with Leuprolide Acetate Plus Norethindrone Acetate Add-Back Therapy
por: Soliman, Ahmed M., et al.
Publicado: (2016)

Preparation and evaluation of a phospholipid-based injectable gel for the long term delivery of leuprolide acetaterrh
por: Long, Danhong, et al.
Publicado: (2016)

Inflammatory myopathy and severe rhabdomyolysis induced by leuprolide acetate therapy for prostate cancer: a case report
por: Bergner, Michael, et al.
Publicado: (2011)

Effects of leuprolide acetate on the quality of life of patients with prostate cancer: A prospective longitudinal cohort study
por: Kim, Myung Soo, et al.
Publicado: (2021)

Treatment with Depot Leuprolide Acetate in Girls with Idiopathic Precocious Puberty: What Parameter should be Used in Deciding on the Initial Dose?
por: Vurallı, Doğuş, et al.
Publicado: (2020)

Efficacy and Safety of Leuprolide Acetate 6-Month Depot for the Treatment of Central Precocious Puberty: A Phase 3 Study
por: Klein, Karen O, et al.
Publicado: (2023)

Myocardial Infarction in a Premenopausal Woman on Leuprolide Therapy
por: Perez, Irving E., et al.
Publicado: (2015)

Bazedoxifene/conjugated estrogens in combination with leuprolide for the treatment of endometriosis
por: Hill, Amanda M., et al.
Publicado: (2018)

SUN-421 Leuprolide Injection Induced Pituitary Apoplexy
por: Jaggi, Shirin, et al.
Publicado: (2019)

Determination of Leuprolide–Fatty Acid Conjugate in Rat Plasma Using LC-MS/MS and Its Pharmacokinetics after Subcutaneous Administration in Rats
por: Seong, Gi-Sang, et al.
Publicado: (2022)

Efficacy of Leuprolide Acetate 1-Month Depot for Central Precocious Puberty (CPP): Growth Outcomes During a Prospective, Longitudinal Study
por: Lee, Peter A, et al.
Publicado: (2011)

Multicenter clinical trial of leuprolide acetate depot (Luphere depot 3.75 mg) for efficacy and safety in girls with central precocious puberty
por: Kim, You Jin, et al.
Publicado: (2013)

Shock From Twisting Peaks: A Rare Case of Recurrent Torsades de Pointes Secondary to Leuprolide-Induced Prolonged QT
por: Abbasi, Danish, et al.
Publicado: (2020)

SAT-037 Effect of Weight on Serum Testosterone with Subcutaneous Testosterone Enanthate in Men with Testosterone Deficiency
por: Bhattacharya, Rajib, et al.
Publicado: (2020)

Effect of Leuprolide Acetate, a GnRH Agonist, on Neuroinflammation and Anxiety-Like Behavior after Mild Hypoxic-Ischemic Encephalopathy in Rat Model
por: Pedroza-García, Karina Alejandra, et al.
Publicado: (2023)

Persistent genital arousal disorder: Successful treatment with leuprolide (antiandrogen)
por: Deka, Kamala, et al.
Publicado: (2015)

PMON70 Systemic Delivery of Leuprolide via Oral Administration
por: Shangold, Gary, et al.
Publicado: (2022)

A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients
por: Tunn, Ulf W
Publicado: (2011)

Change in Estradiol Levels among Premenopausal Patients with Breast Cancer Treated Using Leuprolide Acetate 11.25 Milligrams 3-Month Depot and Tamoxifen
por: Lee, Young-jin, et al.
Publicado: (2020)

Serum Testosterone Concentrations Remain Stable Between Injections in Patients Receiving Subcutaneous Testosterone
por: McFarland, Julie, et al.
Publicado: (2017)

Delayed Oral Estradiol Combined with Leuprolide Increases Endometriosis-Related Pain
por: Hurst, Bradley S., et al.
Publicado: (2000)

Efficacy of Nasal Testosterone Gel (Natesto(®)) Stratified by Baseline Endogenous Testosterone Levels
por: Gronski, Matthew A, et al.
Publicado: (2019)

Maintaining consistency in an EOSCTA system
por: Bachmann, Richard
Publicado: (2022)

The Ideal Goal of Testosterone Replacement Therapy: Maintaining Testosterone Levels or Managing Symptoms?
por: Moon, Du Geon, et al.
Publicado: (2019)

Leuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: evidence review and economic evaluation
por: Wex, Jaro, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_i6c24l4i2i024a3o78d4adqrft